NCT00268957已完成3 期
A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis
Genzyme, a Sanofi Company28 个研究点 分布在 1 个国家目标入组 217 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 217
- 试验地点
- 28
- 主要终点
- Demonstrate the efficacy of sevelamer carbonate powder dosed QD with the largest meal to sevelamer hydrochloride tablets dosed TID with meals on the control of serum phosphorus
研究概览
简要总结
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States. This study aims to evaluate the safety and efficacy of sevelamer carbonate powder dosed once-a-day (QD) with the largest meal compared to sevelamer hydrochloride tablets dosed three-times-per-day (TID) with meals. The total length of participation is approximately 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •On three times per week hemodialysis for three months or longer
- •Currently on a phosphate binder(s)
- •Considered compliant with phosphate binders and hemodialysis therapy
- •Willing to avoid any intentional changes in diet such as fasting or dieting
- •Have the following documented local laboratory measurements:a.Two most recent consecutive serum phosphorus measurements that are ≥ 3.0 and ≤ 6.5 (6.5) mg/dL within 60 days of screening; b.A most recent intact parathyroid hormone (iPTH) measurement ≤ 800 pg/mL within 90 days of screening
- •Have the following central laboratory measurements: a.A serum phosphorus measurement > 5.5 mg/dL at randomization (Week 0);b.A serum iPTH measurement ≤ 800 pg/mL at screening
- •Have not participated in any other investigational drug studies within 30 days prior to enrollment
- •Level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel
- •Willing and able to take sevelamer alone as a phosphate binder for the duration of the study
- •Willing and able to maintain screening doses of lipid medication for the duration of the study, except for safety reasons
- •Willing and able to avoid antacids and phosphate binders containing aluminum, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement
- •If female and of childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout the study, which includes barrier methods, hormones, or intrauterine devices (IUDs)
- •Life expectancy of 12 months or greater
- •Willing and able to provide informed consent
排除标准
- •Active bowel obstruction, dysphagia, swallowing disorder, or severe gastrointestinal (GI) motility disorders
- •Active ethanol or drug abuse, excluding tobacco use
- •In the opinion of the Investigator, subject has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition
- •Use of anti-arrhythmic or anti-seizure medications for the use of arrhythmia or seizure disorders
- •Known hypersensitivity to sevelamer or any constituents of the study drug
- •Pregnant or breast-feeding
- •Evidence of active malignancy except for basal cell carcinoma of the skin
- •Unable to comply with the requirements of the study
- •Any other condition which, in the opinion of the Investigator, will prohibit the subject's inclusion in the study
研究组 & 干预措施
1
Experimental
sevelamer carbonate powder
干预措施: Sevelamer carbonate (Renvela®) (Drug)
2
Active Comparator
Sevelamer hydrochloride
干预措施: Sevelamer hydrochloride (Renagel®) (Drug)
结局指标
主要结局
Demonstrate the efficacy of sevelamer carbonate powder dosed QD with the largest meal to sevelamer hydrochloride tablets dosed TID with meals on the control of serum phosphorus
时间窗: Up to 24 weeks
Evaluate the safety and tolerability of sevelamer carbonate powder dosed QD with the largest meal compared to sevelamer hydrochloride tablets dosed TID with meals
时间窗: Up to 24 weeks
次要结局
- Compare sevelamer carbonate powder dosed QD with the largest meal to sevelamer hydrochloride tablets TID with meals on serum calcium-phosphorus product and serum lipid profile(Up to 24 weeks)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
4 期
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney DiseaseCKD Anemia in Dialysis ParticipantsNCT04059913FibroGen318
终止
不适用
Strong Kidney Initiative Trial for Dialysis Care QualityHemodialysis ComplicationNCT05240573China Medical University Hospital181
已完成
2 期
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)AnaemiaNCT03029247GlaxoSmithKline105
已完成
不适用
DDEP for Lifestyle Modification in Chronic Kidney DiseaseChronic Kidney DiseasesNCT06226649National Cheng Kung University120
已完成
不适用
Renal Effects of Melatonin Trial in Chronic Kidney DiseaseChronic Kidney DiseasesNCT04336566University of Oklahoma31